Associations of serum uric acid with total and cause-specific mortality: Findings from individuals and pooling prospective studies

Authors:

Mohsen Mazidi | Niki Katsiki | Dimitri P. Mikhailidis | Maciej Banach | on behalf of theLipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group

Abstract:

Background and aims

There is considerable controversy regarding the link between serum uric acid (SUA) and mortality. We prospectively evaluated the association between SUA and risk of total and cause specific (coronary heart disease [CHD], cerebrovascular and cancer) mortality by using the National Health and Nutrition Examination Surveys (NHANES, 1999–2010). Furthermore, a systematic review and meta-analysis of cohort studies was performed to investigate pooled associations of SUA with all-cause and cause-specific mortality.

Methods

Vital status through December 31, 2011 was ascertained. PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched (up to April 2018). Adjusted Cox proportional hazard regression models were used to determine the association between SUA and mortality. The DerSimonian-Laird method and generic inverse variance methods were used for quantitative data synthesis.

Results

Overall, 21,025 individuals were included (mean age = 47.6 years, 48.7% men) and 3520 deaths occurred during the 144 months of follow-up. In adjusted models, individuals in the highest quartile of SUA had 10 and 8% greater risk of CHD and stroke mortality, whereas there was no link between SUA, all-cause and cancer mortality. The associations of CHD and stroke mortality with SUA were more pronounced in women and, among women, in those aged >50 years. Furthermore, all-cause mortality was positively and significantly related to SUA concentrations only in women. In the meta-analysis, SUA was shown to predict the risk of total (21%), CHD (24%) and stroke (29%) mortality. Furthermore, participants with a higher level of central adiposity had a greater risk of mortality from CHD and stroke for the same level of SUA.

Conclusions

Our results highlight the adverse impact of SUA on mortality, particularity in older (>50 years) women. The clinical implications of these findings remain to be established in future trials.

  1. Ezzati M., Riboli E.,
    Behavioral and dietary risk factors for noncommunicable diseases.
    N. Engl. J. Med. 2013; 369: 954-964
  2. Borghi C., Cicero A.F.G.
    Serum uric acid and cardiometabolic disease: another brick in the wall?.
    Hypertension. 2017; 69: 1011-1013
  3. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html
  4. Ma C., Avenell A., Bolland M., Hudson J., Stewart F., Robertson C., et al.
    Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis.
    Br. Med. J. 2017; 359: j4849
  5. Sinha S., Singh S.N., Ray U.S.
    Total antioxidant status at high altitude in lowlanders and native highlanders: role of uric acid.
    High Alt. Med. Biol. 2009; 10: 269-274
  6. Freedman D.S., Williamson D.F., Gunter E.W., Byers T.
    Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study.
    Am. J. Epidemiol. 1995; 141: 637-644
  7. Liese A.D., Hense H.W., Lowel H., Doring A., Tietze M., Keil U.
    Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases.
    Epidemiology. 1999; 10: 391-397
  8. Feig D.I., Kang D.H., Johnson R.J.
    Uric acid and cardiovascular risk.
    N. Engl. J. Med. 2008; 359: 1811-1821
  9. Bos M.J., Koudstaal P.J., Hofman A., Witteman J.C., Breteler M.M.
    Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study.
    Stroke. 2006; 37: 1503-1507
  10. Wheeler J.G., Juzwishin K.D., Eiriksdottir G., Gudnason V., Danesh J.
    Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis.
    PLoS Med. 2005; 2: e76
  11. Kim S.Y., Guevara J.P., Kim K.M., Choi H.K., Heitjan D.F., Albert D.A.
    Hyperuricemia and coronary heart disease: a systematic review and meta-analysis.
    Arthritis Care Res. 2010; 62: 170-180
  12. Braga F., Pasqualetti S., Ferraro S., Panteghini M.
    Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis.
    Clin. Chem. Lab. Med. 2016; 54: 7-15
  13. Lehto S., Niskanen L., Ronnemaa T., Laakso M.
    Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus.
    Stroke. 1998; 29: 635-639
  14. Chien K.L., Hsu H.C., Sung F.C., Su T.C., Chen M.F., Lee Y.T.
    Hyperuricemia as a risk factor on cardiovascular events in Taiwan: the Chin-Shan community cardiovascular cohort study.
    Atherosclerosis. 2005; 183: 147-155
  15. Hozawa A., Folsom A.R., Ibrahim H., Nieto F.J., Rosamond W.D., Shahar E.
    Serum uric acid and risk of ischemic stroke: the ARIC Study.
    Atherosclerosis. 2006; 187: 401-407
  16. Koton S., Howard S.C., Warlow C.P., Murphy M.F., Rothwell P.M.
    Serum urate predicts long-term risk of acute coronary events in women after a transient ischaemic attack and stroke.
    Cerebrovasc. Dis. 2008; 26: 517-524
  17. Sakata K., Hashimoto T., Ueshima H., Okayama A.
    Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. National integrated Projects for prospective observation of non-communicable diseases and its trend in the aged.
    Eur. J. Epidemiol. 2001; 17: 461-468
  18. Mazza A., Pessina A.C., Pavei A., Scarpa R., Tikhonoff V., Casiglia E.
    Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly.
    Eur. J. Epidemiol. 2001; 17: 1097-1104
  19. Jee S.H., Lee S.Y., Kim M.T.
    Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men.
    Eur. J. Cardiovasc. Prev. Rehabil. 2004; 11: 185-191
  20. Gerber Y., Tanne D., Medalie J.H., Goldbourt U.
    Serum uric acid and long-term mortality from stroke, coronary heart disease and all causes.
    Eur. J. Cardiovasc. Prev. Rehabil. 2006; 13: 193-198
  21. Strasak A., Ruttmann E., Brant L., Kelleher C., Klenk J., Concin H., et al.
    Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men.
    Clin. Chem. 2008; 54: 273-284
  22. Strasak A.M., Kelleher C.C., Brant L.J., Rapp K., Ruttmann E., Concin H., et al.
    Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study.
    Int. J. Cardiol. 2008; 125: 232-239
  23. Chen J.H., Chuang S.Y., Chen H.J., Yeh W.T., Pan W.H.
    Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study.
    Arthritis Rheum. 2009; 61: 225-232
  24. Holme I., Aastveit A.H., Hammar N., Jungner I., Walldius G.
    Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).
    J. Intern. Med. 2009; 266: 558-570
  25. Kuo C.F., See L.C., Yu K.H., Chou I.J., Chiou M.J., Luo S.F.
    Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality.
    Rheumatology. 2013; 52: 127-134
  26. Ames B.N., Cathcart R., Schwiers E., Hochstein P.
    Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis.
    Proc. Natl. Acad. Sci. U. S. A. 1981; 78: 6858-6862
  27. Mazidi M., Katsiki N., Mikhailidis D.P., Banach M.
    Association of ideal cardiovascular health metrics with serum uric acid, inflammation and atherogenic index of plasma: a population-based survey.
    Atherosclerosis. 2019; 284: 44-49
  28. Milionis H.J., Rizos E., Goudevenos J., Seferiadis K., Mikhailidis D.P., Elisaf M.S.
    Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects.
    Stroke. 2005; 36: 1372-1376
  29. Cicero A.F., Rosticci M., Tocci G., Bacchelli S., Urso R., D’Addato S., et al.
    Serum uric acid and other short-term predictors of electrocardiographic alterations in the Brisighella Heart Study cohort.
    Eur. J. Intern. Med. 2015; 26: 255-258
  30. Culleton B.F., Larson M.G., Kannel W.B., Levy D.
    Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study.
    Ann. Intern. Med. 1999; 131: 7-13
  31. Dobson A.
    Is raised serum uric acid a cause of cardiovascular disease or death?.
    Lancet (London, Engl.). 1999; 354: 1578
  32. Yusuf S., Bosch J.
    Urate levels as a predictor of cardiac deaths: causal relation or mere association?.
    Eur. Heart J. 2002; 23: 760-761
  33. Wannamethee S.G., Shaper A.G., Whincup P.H.
    Serum urate and the risk of major coronary heart disease events.
    Heart (British Cardiac Society). 1997; 78: 147-153
  34. Hu P., Seeman T.E., Harris T.B., Reuben D.B.
    Is serum uric acid level associated with all-cause mortality in high-functioning older persons: MacArthur studies of successful aging?.
    J. Am. Geriatr. Soc. 2001; 49: 1679-1684
  35. Kanellis J., Johnson R.J.
    Editorial comment–Elevated uric acid and ischemic stroke: accumulating evidence that it is injurious and not neuroprotective.
    Stroke. 2003; 34: 1956-1957
  36. Weir C.J., Muir S.W., Walters M.R., Lees K.R.
    Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke.
    Stroke. 2003; 34: 1951-1956
  37. Mazidi M., Katsiki N., Mikhailidis D.P., Banach M.
    Ideal cardiovascular health associated with fatty liver: results from a multi-ethnic survey.
    Atherosclerosis. 2019 May; 284 (Epub 2018 Nov 8): 129-135
    https://doi.org/10.1016/j.atherosclerosis.2018.11.012
  38. Mazidi M., Katsiki N., Banach M.
    A higher flavonoid intake is associated with less likelihood of nonalcoholic fatty liver disease: results from a multiethnic study.
    J Nutr Biochem. 2019 Mar; 65 (Epub 2018 Oct 11): 66-71
    https://doi.org/10.1016/j.jnutbio.2018.10.001
  39. Mazidi M., Huybrechts I., Kengne A.P.
    Associations between serum lipophilic antioxidants levels and non-alcoholic fatty liver disease are moderated by adiposity.
    Eur J Clin Nutr. 2019 Jul; 73 (Epub 2019 Jun 4.PMID: 31164707): 1088-1090
    https://doi.org/10.1038/s41430-019-0413-1
  40. NHANES Statistics
    NCFH: Analytic and Reporting Guidelines.
    http://www.cdc.gov/nchs/data/nhanes/nhanes 03 04/nhanes analytic guidelines dec 2005.pdf
  41. Mazidi M., Katsiki N., Mikhailidis D.P., Sattar N.
    Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies.
    Banach M.Eur Heart J. 2019 Apr 19; (pii: ehz174) ([Epub ahead of print])
    https://doi.org/10.1093/eurheartj/ehz174
  42. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al.
    Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group.
    Jama. 2000; 283: 2008-2012
  43. Stang A.
    Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.
    Eur. J. Epidemiol. 2010; 25: 603-605
  44. Mazidi M., Rezaie P., Ferns G.A., Vatanparast H.
    Impact of Probiotic Administration on Serum C-Reactive Protein Concentrations: Systematic Review and Meta-Analysis of Randomized Control Trials.
    Nutrients. 2017 Jan 3; (pii: E20) (Review): 9
    https://doi.org/10.3390/nu9010020
  45. Mazidi M., Kengne A.P., Banach M.
    Lipid and Blood Pressure Meta-analysis Collaboration Group. Effects of coenzyme Q10 supplementation on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials.
    Pharmacol Res. 2018 Feb; 128 (Epub 2017 Aug 25): 130-136
    https://doi.org/10.1016/j.phrs.2017.08.011
  46. Mazidi M., Karimi E., Rezaie P., Ferns G.A.
    Effects of conjugated linoleic acid supplementation on serum C-reactive protein: a systematic review and meta-analysis of randomized controlled trials.
    Cardiovasc Ther. 2017 Dec; (Review): 35
    https://doi.org/10.1111/1755-5922.12275
  47. Duval S., Tweedie R.
    Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis.
    Biometrics. 2000; 56: 455-463
  48. Borenstein M., Hedges L., Higgins J., Rothstein H.
    Comprehensive Metaanalysis (Vers. 2).
    Biostat. Inc, Englewood Cliffs, NJ2005
  49. Levine W., Dyer A.R., Shekelle R.B., Schoenberger J.A., Stamler J.
    Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago heart association detection Project in Industry.
    J. Clin. Epidemiol. 1989; 42: 257-267
  50. Puddu P.E., Bilancio G., Terradura Vagnarelli O., Lombardi C., Mancini M., Zanchetti A., et al.
    Serum uric acid and eGFR_CKDEPI differently predict long-term cardiovascular events and all causes of deaths in a residential cohort.
    Int. J. Cardiol. 2014; 171: 361-367
  51. Baibas N., Trichopoulou A., Voridis E., Trichopoulos D.
    Residence in mountainous compared with lowland areas in relation to total and coronary mortality. A study in rural Greece.
    J. Epidemiol. Community Health. 2005; 59: 274-278
  52. Harris E.K., Kanofsky P., Shakarji G., Cotlove E.
    Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. II. Estimating biological components of variation.
    Clin. Chem. 1970; 16: 1022-1027
  53. Zuo T., Liu X., Jiang L., Mao S., Yin X., Guo L.
    Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies.
    BMC Cardiovasc. Disord. 2016; 16: 207
  54. Kim S.Y., Guevara J.P., Kim K.M., Choi H.K., Heitjan D.F., Albert D.A.
    Hyperuricemia and risk of stroke: a systematic review and meta-analysis.
    Arthritis Rheum. 2009; 61: 885-892
  55. Zhao G., Huang L., Song M., Song Y.
    Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies.
    Atherosclerosis. 2013; 231: 61-68
  56. Adamopoulos D., Vlassopoulos C., Seitanides B., Contoyiannis P., Vassilopoulos P.
    The relationship of sex steroids to uric acid levels in plasma and urine.
    Acta Endocrinol. 1977; 85: 198-208
  57. Waring W.S., Maxwell S.R., Webb D.J.
    Uric acid concentrations and the mechanisms of cardiovascular disease.
    Eur. Heart J. 2002; 23: 1888-1889
  58. Dawson J., Quinn T., Walters M.
    Uric acid reduction: a new paradigm in the management of cardiovascular risk?.
    Curr. Med. Chem. 2007; 14: 1879-1886
  59. Ruggiero C., Cherubini A., Ble A., Bos A.J., Maggio M., Dixit V.D., et al.
    Uric acid and inflammatory markers.
    Eur. Heart J. 2006; 27: 1174-1181
  60. Mazidi M., Katsiki N., Mikhailidis D.P., Banach M.
    The link between insulin resistance parameters and serum uric acid is mediated by adiposity.
    Atherosclerosis. 2017; 270: 180-186
  61. Cohen M.G., Pascua J.A., Garcia-Ben M., Rojas-Matas C.A., Gabay J.M., Berrocal D.H., et al.
    A simple prediction rule for significant renal artery stenosis in patients undergoing cardiac catheterization.
    Am. Heart J. 2005; 150: 1204-1211
  62. Montalcini T., Gorgone G., Gazzaruso C., Sesti G., Perticone F.,Pujia A.
    Relation between serum uric acid and carotid intima-media thickness in healthy postmenopausal women.
    Int. Emerg. Med. 2007; 2: 19-23
  63. Sumino H., Ichikawa S.,Kanda T., Nakamura T., Sakamaki T.
    Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia.
    Lancet (London, Engl.). 1999; 354: 650
  64. Becker B.F.
    Towards the physiological function of uric acid.
    Free Radical Biol. Med. 1993; 14: 615-631
  65. Nieto F.J., Iribarren C., Gross M.D., Comstock G.W., Cutler R.G.
    Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?.
    Atherosclerosis. 2000; 148: 131-139
  66. Sanchez-Lozada L.G., Tapia E., Avila-Casado C., Soto V., Franco M., Santamaria J., et al.
    Mild hyperuricemia induces glomerular hypertension in normal rats.
    Am. J. Physiol. Renal. Physiol. 2002; 283: F1105-F1110
  67. Mazzali M., Kanellis J., Han L., Feng L., Xia Y.Y., Chen Q., et al.
    Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.
    Am. J. Physiol. Renal. Physiol. 2002; 282: F991-F997
  68. Baker J.F., Krishnan E., Chen L., Schumacher H.R.
    Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?.
    Am. J. Med. 2005; 118: 816-826
  69. De Scheerder I.K., van de Kraay A.M., Lamers J.M., Koster J.F., de Jong J.W., Serruys P.W.
    Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanisms for free radical generation.
    Am. J. Cardiol. 1991; 68: 392-395
  70. Iribarren C., Folsom A.R., Eckfeldt J.H., McGovern P.G., Nieto F.J.
    Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis Risk in Communities.
    Ann. Epidemiol. 1996; 6: 331-340
  71. Gomez M., Vila J., Elosua R., Molina L., Bruguera J., Sala J., et al.
    Relationship of lipid oxidation with subclinical atherosclerosis and 10-year coronary events in general population.
    Atherosclerosis. 2014; 232: 134-140
  72. Suarna C., Dean R.T., May J., Stocker R.
    Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate.
    Arterioscler. Thromb. Vasc. Biol. 1995; 15: 1616-1624
  73. Higgins P., Dawson J., Lees K.R., McArthur K., Quinn T.J., Walters M.R.
    Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis.
    Cardiovasc. Ther. 2012; 30: 217-226
  74. Tomita M., Mizuno S., Yamanaka H., Hosoda Y., Sakuma K., Matuoka Y., et al.
    Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers.
    J. Epidemiol. 2000; 10: 403-409
  75. Khosla U.M., Zharikov S., Finch J.L., Nakagawa T., Roncal C., Mu W., et al.
    Hyperuricemia induces endothelial dysfunction.
    Kidney Int. 2005; 67: 1739-1742
  76. Corry D.B., Eslami P., Yamamoto K., Nyby M.D., Makino H., Tuck M.L.
    Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system.
    J. Hypertens. 2008; 26: 269-275
  77. Perlstein T.S., Gumieniak O., Hopkins P.N., Murphey L.J., Brown N.J., Williams G.H., et al.
    Uric acid and the state of the intrarenal renin-angiotensin system in humans.
    Kidney Int. 2004; 66: 1465-1470
  78. Rosolowsky E.T., Ficociello L.H., Maselli N.J., Niewczas M.A., Binns A.L., Roshan B., et al.
    High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes.
    Clin. J. Am. Soc. Nephrol. : CJASN. 2008; 3: 706-713
  79. Aboa Eboule A.C., De Smet P., Dramaix M., De Backer G., Kornitzer M.
    [Relation between uricemia and total, cardiovascular and coronary mortality in both genders of non-selected sample of the Belgium population].
    Rev. Epidemiol. Sante Publique. 2001; 49: 531-539